Compounds > cryptopine
Page last updated: 2024-11-06

cryptopine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Cryptopine is an alkaloid found in the opium poppy (Papaver somniferum) and other plants. It is a potent inhibitor of the enzyme monoamine oxidase (MAO) and has been shown to have a variety of pharmacological effects, including antidepressant, anti-inflammatory, and anti-cancer activity. Cryptopine is also known to interact with the opioid receptors in the brain, leading to analgesic effects. Due to its complex structure and pharmacological properties, cryptopine has been the subject of numerous research studies, focusing on its potential therapeutic applications. For example, studies have investigated its efficacy in treating depression, inflammation, and cancer. The synthesis of cryptopine involves complex organic chemistry reactions and has been studied extensively to understand its structure and reactivity. Cryptopine is a fascinating molecule with a rich history and ongoing research potential.'

cryptopine: structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID72616
CHEMBL ID1339015
SCHEMBL ID178039
MeSH IDM0050169

Synonyms (43)

Synonym
kryptocavin
cryptocavine
kryptopine
cryptopin
mls000737655 ,
nsc-32984
NSC32984 ,
benzo[e]-1,5-l][2]benzazecin-12(5h)-one, 4,6,7,13-tetrahydro-9,10-dimethoxy-5-methyl-
cryptopine
482-74-6
smr000386998
MLS001048981
brn 0354948
12,13,14,15,-tetrahydro-9,10-dimethoxy-14-methylbenzo(e)-1,3-dioxolo(4,5-1)(2)benzazecin-7(6h)-one
benzo(e)-1,3-dioxolo(4,5-l)(2)benzazecin-12(5h)-one, 4,6,7,13-tetrahydro-9,10-dimethoxy-5-methyl-
nsc 32984
einecs 207-584-8
NCGC00017386-01
tnp00336
OPREA1_763951
NCGC00142563-01
NCGC00142563-02
AKOS002141588
2,3-dimethoxy-13-methyl-12,13,14,15-tetrahydro[1,3]benzodioxolo[4,5-c]benzo[g]azecin-5(6h)-one
CHEMBL1339015
NCGC00017386-03
NCGC00017386-02
HMS2268G15
unii-mw13x5yk4a
mw13x5yk4a ,
4-27-00-06652 (beilstein handbook reference)
SCHEMBL178039
cryptopine [mi]
4,6,7,13-tetrahydro-9,10-dimethoxy-5-methylbenzo(g)-1,3-benzodioxolo(4,5-c)azecin-12(5h)-one
W-202849
DTXSID40197463
11,12-dimethoxy-7-methyl-6,8,9,15-tetrahydro[1,3]benzodioxolo[4,5-c]benzo[g]azecin-14(7h)-one
FT-0701441
Q1142307
6,7-dimethoxy-12-methyl-16,18-dioxa-12-azatetracyclo[12.7.0.04,9.015,19]henicosa-1(14),4,6,8,15(19),20-hexaen-3-one
STL561433
482-74-6 (free base)
11,12-dimethoxy-7-methyl-6,8,9,15-tetrahydro-[1,3]dioxolo[4',5':5,6]benzo[1,2-c]benzo[g]azecin-14(7h)-one

Research Excerpts

Effects

ExcerptReferenceRelevance
"Cryptopine has also been recovered from the mother liquor after the separation of thebaine."( Recovery of thebaine and cryptopine from Indian opium.
Chandra, P; Ramanathan, VS, 1980)		1.29

Dosage Studied

ExcerptRelevanceReference
"The present study was designed to evaluate the effect of repeated oral administration of cryptopine at differential dosing regimens (50, 100, 150, 200 mg/kg bwt) in vivo on lipid peroxide measures, glutathione levels (GSH) and activity of glutathione S-transferase (GST) and glutathione reductase (GR) in the liver, spleen, kidney and lung of Male Wistar rats after a 5 day treatment period."( Stimulation of lipid peroxidation and impairment of glutathione-dependent defense system in Wistar rats treated with cryptopine, a rare non-narcotic opium alkaloid.
Aneja, R; Chandra, R; Katyal, A, )		0.56
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Protein Targets (5)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, 2-oxoglutarate OxygenaseHomo sapiens (human)Potency39.81070.177814.390939.8107AID2147
USP1 protein, partialHomo sapiens (human)Potency141.25400.031637.5844354.8130AID743255
cytochrome P450 2D6 isoform 1Homo sapiens (human)Potency0.02510.00207.533739.8107AID891
cytochrome P450 2C19 precursorHomo sapiens (human)Potency10.00000.00255.840031.6228AID899
chromobox protein homolog 1Homo sapiens (human)Potency89.12510.006026.168889.1251AID540317
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (17)

Assay IDTitleYearJournalArticle
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID592712Inhibition of GST-tagged Rad9/recombinant human N-terminal domain of RPA70 DNA binding domain interaction by electrophoretic mobility shift assay2011Bioorganic & medicinal chemistry, Apr-15, Volume: 19, Issue:8
Small molecule inhibitor of the RPA70 N-terminal protein interaction domain discovered using in silico and in vitro methods.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).2014Journal of biomolecular screening, Jul, Volume: 19, Issue:6
A High-Throughput Assay to Identify Inhibitors of the Apicoplast DNA Polymerase from Plasmodium falciparum.
AID1794808Fluorescence-based screening to identify small molecule inhibitors of Plasmodium falciparum apicoplast DNA polymerase (Pf-apPOL).
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (15)

TimeframeStudies, This Drug (%)All Drugs %
pre-19904 (26.67)18.7374
1990's1 (6.67)18.2507
2000's1 (6.67)29.6817
2010's6 (40.00)24.3611
2020's3 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 55.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index55.56 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.87 (4.65)
Search Engine Demand Index87.16 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (55.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
papaverine
Papaverine: An alkaloid found in opium but not closely related to the other opium alkaloids in its structure or pharmacological actions. It is a direct-acting smooth muscle relaxant used in the treatment of impotence and as a vasodilator, especially for cerebral vasodilation. The mechanism of its pharmacological actions is not clear, but it apparently can inhibit phosphodiesterases and it may have direct actions on calcium channels.. papaverine : A benzylisoquinoline alkaloid that is isoquinoline substituted by methoxy groups at positions 6 and 7 and a 3,4-dimethoxybenzyl group at position 1. It has been isolated from Papaver somniferum.		1.9610benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines		antispasmodic drug;
vasodilator agent
protopine
[no description available]		2.4120dibenzazecine alkaloidplant metabolite
isoquinoline
[no description available]		2.1310azaarene;
isoquinolines;
mancude organic heterobicyclic parent;
ortho-fused heteroarene
amonafide
xanafide: salt formulation of amonafide; DNA-intercalating agent and topoisomerase II inhibitor		2.0610isoquinolines
6-hydroxyflavone
6-hydroxyflavone: antioxidant; structure in first source		2.0610hydroxyflavonoid
methyl fluorone black
methyl fluorone black: structure		2.0610
qlt 0267
[no description available]		2.0610
5-(2-naphthalenylmethylidene)-1,3-diazinane-2,4,6-trione
[no description available]		2.0610naphthalenes
noscapine
Noscapine: A naturally occurring opium alkaloid that is a centrally acting antitussive agent.. (-)-noscapine : A benzylisoquinoline alkaloid that is 1,2,3,4-tetrahydroisoquinoline which is substituted by a 4,5-dimethoxy-3-oxo-1,3-dihydro-2-benzofuran-1-yl group at position 1, a methylenedioxy group at positions 6-7 and a methoxy group at position 8. Obtained from plants of the Papaveraceae family, it lacks significant painkilling properties and is primarily used for its antitussive (cough-suppressing) effects.		1.9610aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound		antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite
3-(prop-2-enylthio)-5-thiophen-2-yl-1H-1,2,4-triazole
[no description available]		2.0610aryl sulfide
phenylthiazolylthiourea
Phenylthiazolylthiourea: A dopamine-beta-hydroxylase inhibitor.		2.0610
2-mercaptonaphth(2,3)imidazole
2-mercaptonaphth(2,3)imidazole: exhibits phosphorescence		2.0610
p-201-1
[no description available]		2.0610
thebaine
Thebaine: A drug that is derived from opium, which contains from 0.3-1.5% thebaine depending on its origin. It produces strychnine-like convulsions rather than narcosis. It may be habit-forming and is a controlled substance (opiate) listed in the U.S. Code of Federal Regulations, Title 21 Part 1308.12 (1985). (From Merck Index, 11th ed)		6.9510morphinane alkaloid;
organic heteropentacyclic compound
clivorine
clivorine: isolated from Ligularia dentata; structure in first source		1.9910
ConditionIndicatedRelationship StrengthStudiesTrials
Innate Inflammatory Response
[description not available]		02.0510
Inflammation
A pathological process characterized by injury or destruction of tissues caused by a variety of cytologic and chemical reactions. It is usually manifested by typical signs of pain, heat, redness, swelling, and loss of function.		02.0510
Plasmodium falciparum Malaria
[description not available]		02.110
Malaria, Falciparum
Malaria caused by PLASMODIUM FALCIPARUM. This is the severest form of malaria and is associated with the highest levels of parasites in the blood. This disease is characterized by irregularly recurring febrile paroxysms that in extreme cases occur with acute cerebral, renal, or gastrointestinal manifestations.		02.110